Kura Oncology Conference Call Summary Company Overview - Kura Oncology is a fully integrated commercial stage precision oncology company - The lead program is ziftomenib (commercial name KOMZIFTI), a menin inhibitor approved for relapsed refractory NPM1 mutant AML - Ambitious development plan to move ziftomenib throughout the continuum of care in various combinations, including frontline opportunities with KOMET-017 studies [5][6] Key Points on Ziftomenib (KOMZIFTI) - Launch Experience: - Approved in mid-November 2025, with rapid market entry within a week - Initial revenue of approximately $2.1 million in the first few weeks post-launch [7][8] - Strong physician feedback highlighting efficacy, safety, compatibility with other agents, and once-daily dosing [8] - Market Access: - Over 84% of plans have included KOMZIFTI in their policies within the first three months [9] - Step edits favoring KOMZIFTI over competitors have been observed, indicating strong market momentum [11] - Market Size: - Estimated total addressable market (TAM) for relapsed refractory NPM1 mutant space is approximately $350 million to $400 million annually, with about 6,000 patients per year [15] - Frontline market TAM is estimated to be 20 times larger than the relapsed refractory market, driven by a larger patient population and longer treatment duration [18] - Clinical Development: - Plans to generate multiple clinical data sets in 2026, including combination studies with various regimens [22][23] - Data expected from KOMET-007, Ven/Aza combination, and gilteritinib combination studies [22] Darlifarnib (Farnesyltransferase Inhibitor) - Targeting resistance mechanisms common to multiple therapies, including tyrosine kinase inhibitors [40] - Ongoing studies in renal cell carcinoma and KRAS G12C mutated solid tumors, with updates expected in 2026 [42][44] - Potential to enhance the efficacy of existing therapies and address a large patient population [46] Partnerships and Financial Position - Global partnership with Kyowa Kirin for ziftomenib development and commercialization, with $180 million in additional milestones anticipated [28][31] - Strong cash position of approximately $667 million, allowing for continued development and commercial plans [60] Upcoming Milestones - Expected publications and data releases throughout 2026, including: - Ziftomenib plus Ven/Aza in relapsed refractory setting - Combination of ziftomenib plus 7 + 3 - Darlifarnib data in renal cell carcinoma and KRAS G12C settings [61][62] Competitive Landscape - Acknowledgment of emerging competition in the farnesyltransferase inhibitor space, with a focus on enhancing patient outcomes through combination therapies [48][49] Conclusion - Kura Oncology aims to establish leadership in the menin and farnesyltransferase inhibitor markets, with a strong focus on commercial execution and clinical development in 2026 [62]

Core Insights - Kura Oncology aims to differentiate its menin inhibitor, Komzifti, in the market, focusing on growth and achieving a leading share in relapsed/refractory NPM1-mutant AML [1][3] - The company reported $2.1 million in net product revenue for Komzifti in late 2025, with positive feedback from healthcare professionals regarding its efficacy and safety [2][6] - Kura's financial position remains strong with $667.2 million in cash at the end of 2025, despite a net loss of $81 million in Q4 [4][17] Commercial Strategy - Kura's near-term objectives include establishing Komzifti's market presence and expanding its use in frontline AML treatments [1][11] - The company has engaged payers covering approximately 90% of insured lives, achieving rapid market access with 84% of private payers establishing coverage within 90 days of approval [8][9] - Komzifti was quickly added to NCCN guidelines as a Category 2A recommendation, reflecting strong support from clinical leaders [7] Product Development - Kura is advancing the KOMET-017 program to move ziftomenib earlier in AML treatment, with recruitment ongoing at around 200 sites [5][12] - The company is exploring combinations of ziftomenib with other therapies, including venetoclax and FLT3 inhibitors, to enhance treatment efficacy [13][14] - Data updates from ongoing trials are expected in 2026, which may support accelerated approval for ziftomenib in newly diagnosed AML [12] Financial Performance - Kura's Q4 2025 net product revenue was $2.1 million, marking a significant increase from the previous year [16] - The first commercial sale triggered a $135 million milestone payment, contributing to a strong cash position [4][17] - Collaboration revenue is projected to be between $45 million to $55 million in 2026, with expectations of continued funding for the ziftomenib program through 2028 [18] Future Outlook - Kura's 2026 priorities include accelerating Komzifti uptake, achieving quarter-over-quarter revenue growth, and executing its strategy to move ziftomenib to frontline treatment [19] - The company plans to publish combination data to guide treatment decisions and provide updates on its FTI platform [19]

Financial Data and Key Metrics Changes - Kura Oncology reported net product revenue of $2.1 million from Komzifti sales in Q4 2025, compared to none in Q4 2024 [16] - Collaboration revenue from the partnership with Kyowa Kirin was $15.2 million, down from $53.9 million in the same period in 2024 [16] - Research and development expenses increased to $64.4 million from $52.3 million in Q4 2024, driven by ziftomenib combination trials [16] - Sales, general, and administrative expenses rose to $39.1 million from $24.1 million in Q4 2024, attributed to the commercial launch of Komzifti [17] - The net loss for Q4 2025 was $81 million, compared to a net loss of $19.2 million in Q4 2024 [17] - Cash equivalents and short-term investments as of December 31, 2025, were $667.2 million, down from $727.4 million at the end of 2024 [17] Business Line Data and Key Metrics Changes - Komzifti generated $2.1 million in net product revenue shortly after its launch, indicating a strong start [3] - The initial U.S. market for NPM1-mutated relapse refractory AML is estimated at approximately $350 million to $400 million annually [10] - Kura anticipates a total U.S. opportunity across relapsed refractory and frontline AML of approximately $7 billion [4] Market Data and Key Metrics Changes - Prescription trends for Komzifti are strong, with positive feedback from physicians and pharmacists regarding its clinical activity and ease of use [7] - Approximately 84% of private payers established coverage for Komzifti within 90 days of approval, surpassing industry benchmarks [9] - Certain blue plans are requiring patients to use Komzifti before allowing coverage for other approved menin inhibitors, indicating a competitive advantage [9] Company Strategy and Development Direction - Kura's strategy focuses on executing commercially, expanding development of ziftomenib across the AML treatment continuum, and advancing a pipeline with meaningful catalysts in 2026 [5] - The company aims to position ziftomenib as a foundational combination partner in AML, including with FLT3 inhibitors and standard backbone regimens [4] - Kura is advancing a focused solid tumor strategy alongside its AML initiatives [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong early launch of Komzifti and its potential to establish leadership in the menin inhibitor class [6] - The company is focused on quarter-over-quarter growth, net revenue, and new patient starts, with plans to provide additional metrics to track progress [10] - Management highlighted the importance of combination therapies in driving better outcomes for patients and gaining market share [42] Other Important Information - Komzifti is now listed in the FDA's Orange Book with patent protection through July 2044, enhancing the long-term value of the franchise [4] - Kura expects to provide guidance for collaboration revenue of $45 million to $55 million in 2026, with anticipated milestones of $180 million under the collaboration agreement with Kyowa Kirin [18] Q&A Session Summary Question: Can you provide more information about the step editing policy from payers? - Management noted that some payers are recommending Komzifti before other menin inhibitors based on its differentiated profile, particularly its cost predictability and safety [25][26] Question: Can you comment on patient demand versus revenue generation? - Management indicated that the launch has been strong, with positive feedback from physicians and expectations for increased patient demand as more data becomes available [33] Question: What do you see as the biggest hurdle for Komzifti to gain market share in 2026? - Management identified the need to get incident patients onto therapy as a key challenge, with no significant payer hurdles reported [40] Question: How do you plan to maximize the FLT3 opportunity? - Management emphasized the importance of combining ziftomenib with FLT3 inhibitors to capture a significant portion of the AML market, as FLT3 mutations represent a large patient population [64] Question: What are the expectations for duration of therapy with Komzifti? - Management stated that while it is early to provide specific data, they expect patients to be treated for up to six months, with ongoing assessments of treatment duration as more data becomes available [87]

Core Insights - Kura Oncology's KOMZIFTI (ziftomenib) is generating early revenue momentum and has received positive feedback from the market, emphasizing its differentiated safety and convenience, which supports ongoing development plans targeting up to 50% of AML patients [1][2] Financial Performance - The company reported a net product revenue of $2.1 million in Q4 2025, based on approximately five weeks of commercial sales following the FDA approval on November 13 [5][13] - Collaboration revenue for Q4 2025 was $15.2 million, a decrease from $53.9 million in Q4 2024, reflecting non-cash revenue recognition under the collaboration agreement with Kyowa Kirin [13] - The net loss for Q4 2025 was $81.0 million, compared to $19.2 million for the same period in 2024 [13] Product Development and Pipeline - KOMZIFTI has been granted full FDA approval for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation [5] - The company has initiated pivotal KOMET-017 Phase 3 frontline trials evaluating ziftomenib in combination with chemotherapy for patients with NPM1-m or KMT2A-rearranged AML [4] - Multiple clinical data milestones are expected in 2026 across AML and solid tumor programs, including ziftomenib's development in gastrointestinal tumors and darlifarnib in renal cell carcinoma [2][6] Market Position and Strategy - KOMZIFTI has been added to the NCCN Clinical Practice Guidelines as a Category 2A recommended treatment option for adults with R/R NPM1-m AML [5] - Approximately 80% of private payers established published coverage policies for KOMZIFTI within the first 90 days of its launch, all aligned with the label and without additional restrictions [5] - The company has a strong capital position with $667.2 million in cash and equivalents, expected to support the advancement of ziftomenib through to the topline results from the first pivotal Phase 3 trial anticipated in 2028 [8][9] Future Outlook - Kura expects 2026 to be a data-rich year with multiple potential value inflection points, including ongoing enrollment in pivotal trials and the advancement of next-generation therapies [6][9] - The company aims to establish clear differentiation in the menin inhibitor class and achieve leading class share in the R/R NPM1-m AML setting [7]

Kura Oncology Conference Call Summary Company Overview - Kura Oncology (NasdaqGS: KURA) is focused on developing therapies for cancer, particularly acute myeloid leukemia (AML) and solid tumors. [1] - The company is in a strong cash position, financed through top-line results in frontline AML. [4] Key Product: KOMZIFTI - KOMZIFTI is Kura's first commercial product, launched for NPM1-mutated AML, with a focus on establishing market leadership. [2] - The product has shown over 21% of patients achieving a Complete Response (CR) or CR with partial hematologic recovery, with a median duration of response of five months. [5][6] - Feedback from clinicians has been positive, highlighting efficacy, safety, and ease of use as differentiating factors. [9][10] Market Potential - The total addressable market (TAM) for relapsed refractory NPM1 mutant AML is estimated to be between $350 million and $400 million. [15] - Kura aims to capture a significant share of this market, with a consensus sales estimate of $48 million for KOMZIFTI in 2026. [12][13] Clinical Trials and Development - Kura is conducting two Phase 3 trials (KOMET-017) for KOMZIFTI, targeting both intensive and non-intensive chemotherapy options. [17][18] - The trial design allows for rapid site engagement and aims to cover a broad patient population. [18] - Kura is also exploring combinations with other agents, such as Quizartinib and Gilteritinib, to enhance treatment efficacy. [31][32] Competitive Landscape - Kura acknowledges competition from other companies developing menin inhibitors, such as Johnson & Johnson and Sumitomo, but believes it has a competitive edge due to its advanced development and market strategy. [36][37] Financial Position - Kura reported a cash balance of over $650 million, with additional milestones of $180 million tied to Phase 3 trials. [55] - The company is positioned to maintain operations through key value inflection points without immediate need for additional financing. [56] Future Outlook - Kura plans to release further clinical data in 2026, which is expected to validate its treatment mechanisms and support ongoing development efforts. [53] - The company is also pursuing regulatory approval in the EU for KOMZIFTI, aiming to enhance its market presence. [16] Additional Insights - Kura is exploring the use of menin inhibitors for diabetes and cardiometabolic diseases, indicating a potential expansion of its therapeutic focus. [4] - The company is committed to developing combination therapies in oncology, recognizing that AML is not typically treated with monotherapy. [33]

Core Insights - Kura Oncology has launched KOMZIFTI™ (ziftomenib), the first and only once-daily oral menin inhibitor approved for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML) [1][10] - The company reported $2.1 million in net product revenue from KOMZIFTI for the initial five-week period following its commercial sale [1][6] - Kura is positioned for significant advancements in 2026 with a robust pipeline of potentially transformative therapies [1][2] Financial Highlights - KOMZIFTI generated $2.1 million in net product revenue from November 21, 2025, to December 31, 2025 [6] - The company expects milestone payments of $195 million from a collaboration agreement with Kyowa Kirin in Q4 2025 [6] - Estimated collaboration revenue for Q4 2025 is between $15 million to $17 million [6] - Kura had $667.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025 [6] Recent Program Highlights - KOMZIFTI received full FDA approval on November 13, 2025, for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation [6] - The drug was added to the NCCN Clinical Practice Guidelines as a Category 2A recommended treatment option for adults with R/R NPM1-m AML [6] - Positive data from the ongoing Phase 1a/1b KOMET-007 trial were presented at the ASH 2025 meeting, showing favorable safety and efficacy in combination with venetoclax and azacitidine [6] - The Phase 3 KOMET-017 trial began in September 2025, evaluating ziftomenib in combination with chemotherapy for newly diagnosed patients [6] Expected 2026 Key Milestones - Accelerate U.S. uptake of KOMZIFTI in R/R NPM1-m AML and drive quarter-over-quarter growth in net product revenue [12] - Present updated data from the KOMET-007 trial and publish combination data in the first half of 2026 [12] - Expand ziftomenib to non-AML indications and advance enrollment in various clinical trials throughout 2026 [12] - Anticipate non-cash collaboration revenue recognition of $45 million to $55 million in 2026 [12]

Core Insights - Kura Oncology's ziftomenib is under FDA Priority Review for adults with relapsed/refractory NPM1-m acute myeloid leukemia (AML), with a target action date of November 30, 2025 [1] - The KOMET 017 Phase 3 trials for ziftomenib are accelerating, targeting over 50% of AML patients by evaluating its combination with intensive and non-intensive chemotherapy [1][5] - The company reported a net loss of $74.1 million for Q3 2025, an increase from a net loss of $54.4 million in Q3 2024, with significant increases in research and development expenses [7][16] Company Updates - Kura Oncology is advancing its ziftomenib program and broader precision oncology pipeline, supported by a strong balance sheet and collaboration with Kyowa Kirin [2] - The first patient was dosed in the KOMET-017 trial in September 2025, which includes two global, randomized, double-blind, placebo-controlled trials [5] - Preliminary clinical data from ziftomenib in combination with venetoclax/azacitidine will be presented at the 2025 ASH Annual Meeting [5][9] Financial Performance - Collaboration revenue for Q3 2025 was $20.8 million, compared to no revenue in Q3 2024 [7][16] - Research and development expenses rose to $67.9 million in Q3 2025 from $41.7 million in Q3 2024 [7][16] - As of September 30, 2025, the company had pro forma cash and equivalents of $609.7 million, expected to support operations into 2027 [7][18]